Roots Analysis has done a detailed
study on
To order this 485+ page report, which features 195+ figures
and 200+ tables, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-/267.html
Key Market Insights
§
§ About 75 drug candidates based on synlet gene
pairs are being evaluated for the treatment of various types of cancers;
presently, there are over 20 screening platforms enabling therapy development
efforts
§ The
pipeline features both small molecules and biologic drugs based on different
synlet targets for treating a variety of oncological and non-oncological
indications
§ Innovation
in this domain is evident across the plethora of scientific articles published
in prestigious journals, highlighting key focus areas and prevalent / upcoming
trends
§ Over time,
several non-profit organizations have extended financial support to aid
research efforts in this domain; the current focus appears to be on the
identification of novel synlet targets across different clinical conditions
§ Significant
advances in research have led to the discovery of a wide array of synlet
targets; over time, substantial intellectual capital has been generated and
validated by eminent scientists from renowned research institutes
§ To
support innovation, several private and public investors have made substantial
capital investments, totalling to approximately USD 5.1 billion, across 100
instances of funding
§ The
personalized approach offered by companion diagnostics presents enormous
opportunities for drug developers to partner with diagnostic test providers to
improve patient / subject selection in clinical trials
§ Future
growth of the market is likely to be driven by the success of clinical outcomes
of late-stage molecules; industry stakeholders are optimistic about the vast
potential of PARP inhibitors
§ In the
mid to long term, the anticipated market opportunity is likely to be well
distributed across advanced cancer indications, delivery routes and various
global regions
For more information, please visit https://www.rootsanalysis.com/reports/view_document/synthetic-lethality-based-drugs-and-targets-market-2019-2030-focus-on-dna-repair-including-parp-inhibitors-and-other-novel-cellular-pathways/267.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION TO DNA DAMAGE
AND REPAIR SYSTEMS
3.1. Chapter Overview
3.2. Overview of Deoxyribonucleic
Acid (DNA) Damage
3.3. DNA Damaging Agents
3.3.1. Endogenous DNA Damaging Agents
3.3.2. Exogenous DNA Damaging Agents
3.3.3. Other DNA Damaging Agents
3.4. DNA Damage Response System
3.4.1. Key Components of DNA Repair
System
3.5. Types of DNA Repair Systems
3.5.1. Direct Repair
3.5.1.1. Photoreactivation
3.5.1.2. Alkyl Transferase Mediated Direct
DNA Repair
3.5.1.3. AlkB Mediated Direct DNA Repair
3.5.1.4. DNA Ligase Mediated Direct DNA
Repair
3.5.2. Excision Repair
3.5.2.1. Base Excision Repair (BER)
3.5.2.1.1. BER Pathway: Key Enzymes
3.5.2.1.1.1. DNA Glycosylases
3.5.2.1.1.2. Apurinic / Apyrimidinic (AP)
Endonucleases
3.5.2.1.1.3. Other Enzymes
3.5.2.1.2. Short-Patch Base Excision Repair
3.5.2.1.3. Long-Patch Base Excision Repair
3.5.2.2. Nucleotide Excision Repair (NER)
3.5.2.3. Mismatch Repair
3.5.3. Indirect Repair
3.5.3.1. Homologous Recombination Repair
(HRR)
3.5.3.2. Non-Homologous End-Joining
3.6. Mutations in DNA Repair Genes
4. INTRODUCTION TO SYNTHETIC
LETHALITY
4.1. Chapter Overview
4.2. Concept of Synthetic
Lethality
4.2.1. Historical Evolution of
Synthetic Lethality
4.2.2. HRR and Synthetic Lethality
4.2.3. Other Synthetic Lethal Gene
Interactions
4.2.4. Advantages of Synthetic
Lethality
4.2.5. Limitations of Synthetic
Lethality
4.3. Identification of Synlet
Interactions
4.3.1. Hypothesis-Driven Approach
4.3.2. Screening-Based Approaches
4.3.2.1. Chemical Library-Based Screening
Approaches
4.3.2.1.1. Non-Annotated Libraries
4.3.2.1.2. Annotated Libraries
4.3.2.2. Genome-Wide Interference-Based
Screening Approaches
4.3.2.2.1. Ribonucleic Acid Interference (RNAi)
Based Synlet Target Identification
4.3.2.2.2. Clustered Regularly Interspaced Short
Palindromic Repeats (CRISPR) Based Synlet Target Identification
4.3.3. In Silico Approaches
4.4. Prevalent Trends Related to
Synthetic Lethality
4.4.1. Recent News on Google: Emerging
Focus Areas
4.4.2. Google Trends Analysis:
Historical Timeline
4.4.3. Google Trends Analysis:
Geographical Activity
4.4.4. Google Trends Analysis: Other
Key Terms Related to Synthetic Lethality
4.5 Concluding Remarks
5. MARKET OVERVIEW
5.1. Chapter Overview
5.2. Synthetic Lethality-based
Drugs: Marketed and Development Pipeline
5.2.1. Analysis by Phase of Development
5.2.2. Analysis by Type of Molecule
5.2.3. Analysis by Type of Therapy
5.2.4. Analysis by Type of Synlet
Target
5.2.5. Analysis by Therapeutic Area
5.2.6. Analysis by Target Indication
5.2.7. Analysis by Patient Segment
5.2.8. Analysis by Route of
Administration
5.3. Synthetic Lethality-based
Drugs: List of Screening Platforms
5.4 Synthetic
Lethality-based Drugs: List of Drug Developers / Screening Platform Providers
5.4.1. Analysis by Year of
Establishment
5.4.2. Analysis by Location of
Headquarters
5.4.3. Analysis by Company Size
5.4.4. Analysis by Company Size and
Location of Headquarters
5.4.5. Leading Drug Developers
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Profiles of Established
Players
6.2.1. AbbVie
6.2.1.1. Company Overview
6.2.1.2. Synthetic Lethality-based Drug Portfolio
6.2.1.2.1. Veliparib (ABT-888)
6.2.1.3. Recent Developments and Future
Outlook
6.2.2. AstraZeneca
6.2.2.1. Company Overview
6.2.2.2. Synthetic Lethality-based Drug
Portfolio
6.2.2.2.1. Olaparib (Lynparza®)
6.2.2.2.2. AZD6738
6.2.2.2.3. AZD1775
6.2.2.3. Recent Developments and Future
Outlook
6.2.3. BeiGene
6.2.3.1. Company Overview
6.2.3.2. Synthetic Lethality-based Drug
Portfolio
6.2.3.2.1. Pamiparib (BGB-290)
6.2.3.3. Recent Developments and Future
Outlook
6.2.4. Clovis Oncology
6.2.4.1. Company Overview
6.2.4.2. Synthetic Lethality-based Drug
Portfolio
6.2.4.2.1. Rucaparib (Rubraca®)
6.2.4.3. Recent Developments and Future
Outlook
6.2.5. GlaxoSmithKline
6.2.5.1. Company Overview
6.2.5.2. Synthetic Lethality-based Drug Portfolio
6.2.5.2.1. Niraparib (Zejula®)
6.2.5.3. Recent Developments and Future
Outlook
6.2.6. Pfizer
6.2.6.1. Company Overview
6.2.6.2. Synthetic Lethality-based Drug
Portfolio
6.2.6.2.1. Talazoparib (TALZENNA®)
6.2.6.3. Recent Developments and Future Outlook
6.3. Profiles of Small and
Mid-Sized Players
6.3.1. AtlasMedx
6.3.2. Chordia Therapeutics
6.3.3. IDEAYA Biosciences
6.3.4. Mission Therapeutics
6.3.5. Repare Therapeutics
6.3.6. Sierra Oncology
6.3.7. SyntheX Labs
7. EMERGING TRENDS ON SOCIAL
MEDIA
7.1. Chapter Overview
7.2. Scope and Methodology
7.3. Synthetic Lethality: Trends
on Twitter
7.3.1. Cumulative Year-Wise Activity
7.3.2. Historical Trends in Volume of
Tweets
7.3.3. Evolutionary Trend Analysis
7.3.4. Trending Words / Phrases on
Twitter
7.3.5. Most Prolific Contributors on
Twitter
7.3.6. Most Popular Synlet Targets /
Patient Mutations on Twitter
7.3.7. Most Popular Indications on
Twitter
7.3.8. Heat Map Analysis: Distribution
by Synlet Targets / Patient Mutations and Indications
7.4. Most Popular Tweets
7.5. Concluding Remarks
8. PUBLICATION ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Synthetic Lethality: List of
Recent Publications, 2019
8.3.1. Analysis by Type of Publication
8.3.2. Analysis by Study Objective
8.4. Synthetic Lethality:
Publication Analysis, 2017–2019
8.4.1. Analysis by Year of Publication
8.4.2. Emerging Focus Areas
8.4.3. Analysis by Synlet Targets /
Patient Mutations
8.4.3.1. Most Popular Synlet Targets /
Patient Mutations
8.4.3.2. Year-Wise Trend in Activity for
Popular Synlet Targets / Patient Mutations
8.4.4. Analysis by Target Indications
8.4.4.1. Most Popular Target Indications
8.4.4.2. Year-Wise Trend in Activity for
Popular Target Indications
8.4.5. Analysis by Key Research
Journals
8.4.5.1. Key Journals Based on Number of
Publications
8.4.5.2. Analysis by Journal Impact Factor
8.4.5.3. Key Journals Based on Journal
Impact Factor
8.4.6. Key Research Hubs
8.4.7. Most Popular Authors
8.4.8. Analysis of Publications with
Grant Support
8.4.8.1. Most Popular Grant Bodies
8.4.8.2. Location of Grant Bodies
8.5. Publication Benchmark
Analysis
9. ABSTRACT ANALYSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Synthetic Lethality: List of
American Society of Clinical Oncology Abstracts
9.3.1. Analysis by Year of Publication
9.3.2. Emerging Focus Areas
9.3.3. Most Popular Drugs
9.3.4. Most Popular Synlet Targets /
Patient Mutations
9.3.5. Most Popular Target Indications
9.3.6. Most Popular Principal Authors
9.3.6.1. Analysis by Locations of Principal
Authors
9.3.6.2. Analysis by Type of Organization of
Principal Authors
9.3.6.3. Analysis by Active Organization
9.3.6.4. Analysis by Author Designation
9.3.6.5. Most Popular Authors
10. ACADEMIC GRANTS ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Synthetic Lethality: List of
Grants Awarded by National Institutes of Health
10.3.1. Analysis by Year of Award
10.3.2. Analysis by Amount Awarded
10.3.3. Analysis by Administering
Institute Center
10.3.4. Analysis by Funding Institute
Center
10.3.5. Analysis by Support Period
10.3.6. Analysis by Funding Institute
Center and Support Period
10.3.7. Most Popular National Institute of
Health (NIH) Funding Categorization
10.3.8. Analysis by Funding Mechanism
10.3.9. Analysis by Emerging Focus Areas
10.3.10. Most Popular Synlet Targets /
Patient Mutations
10.3.11. Most Popular Target Indications
10.3.12. Analysis by Type of Grant Application
10.3.13. Most Popular NIH Departments
10.3.14. Analysis by Study Section
10.3.15. Analysis by Type of Recipient
Organization
10.3.16. Most Popular Recipient Organization
10.3.17. Most Popular Recipient Organization
and NIH Spending Sectors
10.3.18. Analysis by Grant Activity
10.3.19. Most Prominent Program Officers
10.3.20. Regional Distribution of Recipient
Organization
10.4. Grant Attractiveness Analysis
11. FUNDING AND INVESTMENT
ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Synthetic Lethality: List of
Funding and Investments
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Type of Company
11.3.5. Analysis by Purpose of Funding
11.3.6. Analysis by Type of Molecule
11.3.7. Analysis by Synlet Target
11.3.8. Analysis by Therapeutic Area
11.3.9. Analysis by Target Indication
11.3.10. Analysis by Geography
11.3.11. Most Active Players
11.3.12. Most Active Investors
11.4. Concluding Remarks
12. TARGET BENCHMARK ANALYSIS
12.1. Chapter Overview
12.2. Scope and Methodology
12.3. Target Benchmark Analysis
12.3.1. Clinically Validated Synlet
Targets
12.3.2. Preclinically Validated Synlet
Targets
12.3.3. Early Stage Research Validated
Synlet Targets
12.4. Initiatives of Big
Pharmaceutical Players
12.5. Concluding Remarks
13. ROLE OF COMPANION
DIAGNOSTICS IN SYNTHETIC LETHALITY
13.1. Chapter Overview
13.2. Concept of Companion
Diagnostics
13.3. Development of Companion
Diagnostics
13.3.1. Co-development / Parallel
Development Approach
13.3.2. Development of Companion
Diagnostics Post Drug Approval
13.3.3. Development
of already Approved Companion Diagnostics for New Drugs / Disease Indications
13.4. Advantages of Companion
Diagnostics
13.5. Applications of Companion
Diagnostics in Synthetic Lethality
13.6. Companion Diagnostics: List of
Available / Under Development Tests
13.6.1. Analysis by Synlet Target
13.6.2. Analysis by Type of Biomarker
13.6.3. Analysis by Type of Biomarker and
Technology
13.6.4. Analysis by Target Indication
13.6.5. Analysis by Developer and Synlet
Target
13.6.6. Most Prominent Developers
13.7. Case-in-Point:
Companion Diagnostics for Commercially Available Poly-ADP Ribose Polymerase
(PARP) Inhibitors
13.7.1. Companion Diagnostics Test for
Niraparib
13.7.1.1. Product Overview
13.7.1.2. Working Process
13.7.1.3. Collaborations
13.7.2. Companion Diagnostics Test for
Olaparib
13.7.2.1. Product Overview
13.7.2.2. Working Process
13.7.2.3. Collaborations
13.7.3. Companion Diagnostics Test for
Rucaparib
13.7.3.1. Product Overview
13.7.3.2. Collaborations
13.7.4. Companion Diagnostics Test for
Talazoparib
13.7.4.1. Product Overview
13.7.4.2. Collaborations
13.8. Future Perspective
14. MARKET FORECAST
14.1. Chapter Overview
14.2. Scope and Limitations
14.3. Forecast Methodology and Key
Assumptions
14.4. Overall Synthetic Lethality-based
Drugs Market, 2019-2030
14.4.1. Synthetic
Lethality-based Drugs Market: Distribution by Type of Molecule, 2019 and 2030
14.4.1.1. Synthetic Lethality-based Drugs Market
for Small Molecule, 2019-2030
14.4.1.2. Synthetic Lethality-based Drugs Market
for Biologic, 2019-2030
14.4.2. Synthetic
Lethality-based Drugs Market: Distribution by Synlet Target, 2019 and 2030
14.4.2.1. Synthetic Lethality-based Drugs Market
for APE1 / REF-1, 2019-2030
14.4.2.2. Synthetic Lethality-based Drugs Market
for CHK1, 2019-2030
14.4.2.3. Synthetic Lethality-based Drugs
Market for GLS1, 2019-2030
14.4.2.4. Synthetic Lethality-based Drugs
Market for PARP, 2019-2030
14.4.2.5. Synthetic Lethality-based Drugs
Market for Polθ, 2019-2030
14.4.2.6. Synthetic Lethality-based Drugs
Market for WEE1, 2019-2030
14.4.3. Synthetic
Lethality-based Drugs Market: Distribution by Target Indication, 2019 and 2030
14.4.3.1. Synthetic Lethality-based Drugs Market
for Breast Cancer, 2019-2030
14.4.3.2. Synthetic Lethality-based Drugs
Market for Cervical / Anogenital Cancer, 2019-2030
14.4.3.3. Synthetic Lethality-based Drugs
Market for Diabetic Macular Edema, 2019-2030
14.4.3.4. Synthetic Lethality-based Drugs
Market for Gastric Cancer, 2019-2030
14.4.3.5. Synthetic Lethality-based Drugs
Market for Lung Cancer, 2019-2030
14.4.3.5. Synthetic Lethality-based Drugs
Market for Ovarian Cancer, 2019-2030
14.4.3.7. Synthetic Lethality-based Drugs
Market for Renal Cell Cancer, 2019-2030
14.4.4. Synthetic
Lethality-based Drugs Market: Distribution by Route of Administration, 2019 and 2030
14.4.4.1. Synthetic Lethality-based Drugs
Market for Oral Therapies, 2019-2030
14.4.4.2. Synthetic Lethality-based Drugs
Market for Intravenous Therapies, 2019-2030
14.4.5. Synthetic
Lethality-based Drugs Market: Distribution by Geography, 2019 and 2030
14.4.5.1. Synthetic Lethality-based Drugs Market
in the US, 2019-2030
14.4.5.2. Synthetic Lethality-based Drugs Market
in France, 2019-2030
14.4.5.3. Synthetic Lethality-based Drugs Market
in Germany, 2019-2030
14.4.5.4. Synthetic Lethality-based Drugs Market
in Italy, 2019-2030
14.4.5.5. Synthetic Lethality-based Drugs Market
in Spain, 2019-2030
14.4.5.6. Synthetic Lethality-based Drugs Market
in the UK, 2019-2030
14.4.5.8. Synthetic Lethality-based Drugs Market
in Australia, 2019-2030
14.4.5.7. Synthetic Lethality-based Drugs Market
in China, 2019-2030
14.4.5.8. Synthetic Lethality-based Drugs Market
in Japan, 2019-2030
14.4.6. Product-wise Sales Forecast
14.4.6.1 Niraparib (GlaxoSmithKline)
14.4.6.1.1. Target Patient Population
14.4.6.1.2. Sales Forecast (USD Million)
14.4.6.1.3. Net Present Value (USD Million)
14.4.6.1.4. Value Creation Analysis
14.4.6.2. Olaparib (AstraZeneca)
14.4.6.2.1. Target Patient Population
14.4.6.2.2. Sales Forecast (USD Million)
14.4.6.2.3. Net Present Value (USD Million)
14.4.6.2.4. Value Creation Analysis
14.4.6.3. Rucaparib (Clovis Oncology)
14.4.6.3.1. Target Patient Population
14.4.6.3.2. Sales Forecast (USD Million)
14.4.6.3.3. Net Present Value (USD Million)
14.4.6.3.4. Value Creation Analysis
14.4.6.4. Talazoparib (Pfizer)
14.4.6.4.1. Target Patient Population
14.4.6.4.2. Sales Forecast (USD Million)
14.4.6.4.3. Net Present Value (USD Million)
14.4.6.4.4. Value Creation Analysis
14.4.6.5. Pamiparib (BeiGene)
14.4.6.5.1. Target Patient Population
14.4.6.5.2. Sales Forecast (USD Million)
14.4.6.5.3. Net Present Value (USD Million)
14.4.6.5.4. Value Creation Analysis
14.4.6.6. Veliparib (AbbVie)
14.4.6.6.1. Target Patient Population
14.4.6.6.2. Sales Forecast (USD Million)
14.4.6.6.3. Net Present Value (USD Million)
14.4.6.6.4. Value Creation Analysis
14.4.6.7. Adavosertib (AstraZeneca)
14.4.6.7.1. Target Patient Population
14.4.6.7.2. Sales Forecast (USD Million)
14.4.6.7.3. Net Present Value (USD Million)
14.4.6.7.4. Value Creation Analysis
14.4.6.8. APX3330 (Apexian Pharmaceuticals)
14.4.6.8.1. Target Patient Population
14.4.6.8.2. Sales Forecast (USD Million)
14.4.6.8.3. Net Present Value (USD Million)
14.4.6.8.4. Value Creation Analysis
14.4.6.9. CX-5461 (Senhwa Biosciences)
14.4.6.9.1. Target Patient Population
14.4.6.9.2. Sales Forecast (USD Million)
14.4.6.9.3. Net Present Value (USD Million)
14.4.6.9.4. Value Creation Analysis
14.4.6.10. SRA737-01 (Sierra Oncology)
14.4.6.10.1. Target Patient Population
14.4.6.10.2. Sales Forecast (USD Million)
14.4.6.10.3. Net Present Value (USD Million)
14.4.6.10.4. Value Creation Analysis
14.4.6.11. SRA737-02 (Sierra Oncology)
14.4.6.11.1. Target Patient Population
14.4.6.11.2. Sales Forecast (USD Million)
14.4.6.11.3. Net Present Value (USD Million)
14.4.6.11.4. Value Creation Analysis
14.4.6.12. Telaglenastat (Calithera Biosciences)
14.4.6.12.1. Target Patient Population
14.4.6.12.2. Sales Forecast (USD Million)
14.4.6.12.3. Net Present Value (USD Million)
14.4.6.12.4. Value Creation Analysis
14.4.7. Concluding Remarks
15. CONCLUDING REMARKS
16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. Artios Pharma
16.2.1. Company / Organization Snapshot
16.2.2. Interview Transcript: Simon
Boulton, Vice President, Science Strategy
16.3. IMPACT Therapeutics
16.3.1. Company / Organization Snapshot
16.3.2. Interview Transcript: Yi Xu,
Associate Director
16.4. Harvard Medical School
16.4.1. Company / Organization Snapshot
16.4.2. Interview Transcript: Norbert
Perrimon, Professor, Department of Genetics
16.5. Panjab University
16.5.1. Company / Organization Snapshot
16.5.2. Interview Transcript: Vivek
Dharwal, Professor, Department of Biochemistry
16.6. UbiQ
16.6.1. Company / Organization Snapshot
16.6.2. Interview Transcript: Alfred
Nijkerk, Chief Executive Officer
17. APPENDIX 1: TABULATED DATA
18. APPENDIX 2: LIST OF
COMPANIES AND ORGANIZATIONS
Contact Details
Gaurav Chaudhary
+1 (415) 800 3415
